利拉鲁肽治疗非酒精性脂肪性肝病的作用机制及研究进展

非酒精性脂肪性肝病（NAFLD）是我国最常见的慢性肝脏疾病之一。大多数病人的肝脂肪变性的发展与饮食中的脂肪摄入有关，其特征为自由脂肪酸摄入增加和肝脏脂肪重新生成，肝细胞中三酰甘油过度积聚。非酒精性脂肪性肝炎是一种由单纯性肝脂肪性变进展为肝细胞死亡、炎症浸润和纤维化状态的代谢性肝病，是NAFLD较严重的状态，是肝硬化、肝癌的重要危险因素。胰高血糖素样肽-1(GLP-1)是回肠内分泌细胞分泌的一种脑肠肽，进餐后血糖升高刺激胰高血糖素样肽-1分泌，抑制α细胞分泌胰高血糖素，防止餐后高血糖。以往的研究中，GLP-1受体激动剂被明确批准用于治疗糖尿病和肥胖症。其中，GLP-1受体激动剂利拉鲁肽除了其降血糖效果外，还对NAFLD存在有益的影响。该文对利拉鲁肽在NAFLD中的作用及机制研究进展做一综述。

Research progress on the mechanism of liraglutide in the treatment of nonalcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in China. The development ofhepatic steatosis in most patients is associated with dietary fat intake, characterized by increased free fatty acid intake and liver fat re.generation, and excessive accumulation of triglyceride in liver cells. Non-alcoholic steatohepatitis (NASH) is a metabolic liver diseasethat develops from simple steatosis to a state of hepatocyte death, inflammatory infiltration and fibrosis. It is a serious state of NAFLDand an important risk factor of liver cirrhosis and liver cancer. Glucagon-like peptide-1 (GLP-1) is a brain-gut peptide secreted by ileal endocrine cells. Postprandial hyperglycemia stimulates GLP-1 secretion, inhibits glucagon secretion by alpha cells, and prevents post. prandial hyperglycemia. In previous studies, GLP-1 receptor agonists were explicitly approved for the treatment of diabetes and obesity. In addition to its hypoglycemic effect, the GLP-1 receptor agonist liraglutide has beneficial effects on NAFLD. This article reviews the role and mechanism of liraglutide in NAFLD.